본문 바로가기
KERD
논문KCI 등재

Soluble receptors in cancer: mechanisms, clinical significance, and therapeutic strategies

이창우|Park Eun-Ji
생화학분자생물학회 (Korean Society Of Biochemistry And Molecular Biology)|2024.12|Experimental and Molecular Medicine|제56권 |pp. 100-109|DOI 10.1038/s12276-023-01150-6

1

조회

0

다운로드

0

인용

0

참고문헌

주제분류생화학

초록

Soluble receptors are soluble forms of receptors found in the extracellular space. They have emerged as pivotal regulators of cellular signaling and disease pathogenesis. This review emphasizes their significance in cancer as diagnostic/prognostic markers and potential therapeutic targets. We provide an overview of the mechanisms by which soluble receptors are generated along with their functions. By exploring their involvement in cancer progression, metastasis, and immune evasion, we highlight the importance of soluble receptors, particularly soluble cytokine receptors and immune checkpoints, in the tumor microenvironment. Although current research has illustrated the emerging clinical relevance of soluble receptors, their therapeutic applications remain underexplored. As the landscape of cancer treatment evolves, understanding and targeting soluble receptors might pave the way for novel strategies for cancer diagnosis, prognosis, and therapy.

Abstract

Soluble receptors are soluble forms of receptors found in the extracellular space. They have emerged as pivotal regulators of cellular signaling and disease pathogenesis. This review emphasizes their significance in cancer as diagnostic/prognostic markers and potential therapeutic targets. We provide an overview of the mechanisms by which soluble receptors are generated along with their functions. By exploring their involvement in cancer progression, metastasis, and immune evasion, we highlight the importance of soluble receptors, particularly soluble cytokine receptors and immune checkpoints, in the tumor microenvironment. Although current research has illustrated the emerging clinical relevance of soluble receptors, their therapeutic applications remain underexplored. As the landscape of cancer treatment evolves, understanding and targeting soluble receptors might pave the way for novel strategies for cancer diagnosis, prognosis, and therapy.

참고문헌 (160)

  1. Heaney, M. L., "Soluble receptors in human disease", J. Leukoc. Biol, 64, pp.135~146 (1998)
  2. Levine, S. J., "Mechanisms of soluble cytokine receptor generation", J. Immunol, 173, pp.5343~5348 (2004)
  3. Kefaloyianni, E., "Soluble forms of cytokine and growth factor receptors : mechanisms of generation and modes of action in the regulation of local and systemic inflammation", FEBS Lett, 596, pp.589~606 (2022)
  4. Li, W., "Soluble immune checkpoints are dysregulated in COVID-19 and heavy alcohol users with HIV infection", Front. Immunol, 13, pp.833310~ (2022)
  5. Chakrabarti, R., "Soluble immune checkpoint mole cules : serum markers for cancer diagnosis and prognosis", Cancer Rep. Hoboken, 2, pp.e1160~ (2019)
  6. Gohda, T., "Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1diabetes", J. Am. Soc. Nephrol, 23, pp.516~524 (2012)
  7. Swiderska, J., "Clinical relevance of soluble forms of immune checkpoint molecules sPD-1, sPD-L1, and sCTLA-4 in the diagnosis and prognosis of ovarian cancer", Diagnostics (Basel), 12, pp.189~ (2022)
  8. Reichl, P., "Accuracy of novel diagnostic biomarkers for hepatocel lular carcinoma : an update for clinicians(Review)", Oncol. Rep, 36, pp.613~625 (2016)
  9. Wang, Q., "Soluble immune checkpoint-related proteins as predictors of tumor recurrence, survival, and T cell phenotypes in clear cell renal cell carci noma patients", J. Immunother. Cancer, 7, pp.334~ (2019)
  10. Brooks, G. D., "IL6 trans-signaling promotes KRAS-driven lung carcinogen esis", Cancer Res, 76, pp.866~876 (2016)
  11. Badoual, C., "The soluble alpha chain of interleukin-15 receptor : a proin f lammatory molecule associated with tumor progression in head and neck cancer", Cancer Res, 68, pp.3907~3914 (2008)
  12. Gu, D., "Soluble immune checkpoints in cancer : production, function and biological significance", J. Immunother. Cancer, 6, pp.132~ (2018)
  13. Lichtenthaler, S. F., "Proteolytic ectodomain shed ding of membrane proteins in mammals-hardware, concepts, and recent developments", EMBO J, 37, pp.e99456~ (2018)
  14. Miller, M. A., "Molecular pathways : receptor ectodomain shedding in treatment, resistance, and monitoring of cancer", Clin. Cancer Res, 23, pp.623~629 (2017)
  15. Smith, T. M. Jr., "Targeting ADAM10 in cancer and autoimmunity", Front. Immunol, 11, pp.499~ (2020)
  16. Dusterhoft, S., "The metalloprotease ADAM17 in inflam mation and cancer", Pathol. Res. Pr, 215, pp.152410~ (2019)
  17. Merilahti, J. A. M., "Gamma-secretase-dependent signaling of receptor tyrosine kinases", Oncogene, 38, pp.151~163 (2019)
  18. Huovila, A. P., "Shedding light on ADAM metalloproteinases", Trends Biochem. Sci, 30, pp.413~422 (2005)
  19. Schumertl, T., "Function and proteolytic generation of the soluble interleukin-6 receptor in health and disease", Biochim Biophys. Acta. Mol. Cell Res, 1869, pp.119143~ (2022)
  20. Lokau, J., "Biological functions and therapeutic opportunities of soluble cytokine receptors", Cytokine Growth Factor Rev, 55, pp.94~108 (2020)
  21. Arai, J., "The immunological role of ADAMs in the field of gastroenterological chronic inflammatory diseases and cancers : a review", Oncogene, 42, pp.549~558 (2023)
  22. Bulanova, E., "Retraction : Soluble interleukin(IL)-15Ralpha is generated by alternative splicing or proteolytic cleavage and forms functional complexes with IL-15", J. Biol. Chem, 286, pp.5934~ (2011)
  23. Blum, H., "Two distinct stimulus dependent pathways lead to production of soluble murine interleukin-4receptor", J. Immunol, 157, pp.1846~1853 (1996)
  24. Lust, J. A., "Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor", Cytokine, 4, pp.96~100 (1992)
  25. Lainez, B., "Identification and characterization of a novel spliced variant that encodes human soluble tumor necrosis factor receptor 2", Int. Immunol, 16, pp.169~177 (2004)
  26. Josephs, S. F., "Unleashing endogenous TNF-alpha as a cancer immu notherapeutic", J. Transl. Med, 16, pp.242~ (2018)
  27. Aderka, D., "Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients", Cancer Res, 51, pp.5602~5607 (1991)
  28. Diez-Ruiz, A., "Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis", Eur. J. Haematol, 54, pp.1~8 (1995)
  29. Nielsen, C., "Alternative splice variants of the human PD-1 gene", Cell Immunol, 235, pp.109~116 (2005)
  30. Oaks, M. K., "A native soluble form of CTLA-4", Cell Immunol, 201, pp.144~153 (2000)
  31. Zhu, X., "Soluble PD-1 and PD-L1 : predictive and prognostic significance in cancer", Oncotarget, 8, pp.97671~97682 (2017)
  32. Hawari, F. I., "Release of full-length 55-kDa TNF receptor 1 in exosome-like vesicles : a mechanism for generation of soluble cytokine receptors", Proc. Natl Acad. Sci. USA, 101, pp.1297~1302 (2004)
  33. Soderberg, A., "Redox signaling transmitted in trans to neighboring cells by melanoma-derived TNF containing exosomes", Free Radic. Biol. Med, 43, pp.90~99 (2007)
  34. Schumacher, N., "Shedding of endogenous Interleukin-6 Receptor(IL-6R)is governed by A Disintegrin and Metalloproteinase(ADAM)proteases while a full length IL-6R isoform localizes to circulating microvesicles", J. Biol. Chem, 290, pp.26059~26071 (2015)
  35. Whiteside, T. L., "Tumor-derived exosomes and their role in cancer progression", Adv. Clin. Chem, 74, pp.103~141 (2016)
  36. Keller, M. D., "Decoy exosomes provide protection against bacterial toxins", Nature, 579, pp.260~264 (2020)
  37. Shimoda, M., "Metalloproteinases in extracellular vesicles", Biochim. Biophys. Acta. Mol. Cell Res, 1864, pp.1989~2000 (2017)
  38. Pegtel, D. M., "Exosomes", Annu. Rev. Biochem, 88, pp.487~514 (2019)
  39. Arnold, P., "Joint reconstituted signaling of the IL-6 receptor via extracellular vesicles", Cells, 9, pp.1307~ (2020)
  40. Al-Nedawi, K., "Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells", Nat. Cell Biol, 10, pp.619~624 (2008)
  41. Zhang, H., "Exosome-delivered EGFR regulates liver microenvironment to promote gastric cancer liver metastasis", Nat. Commun, 8, pp.15016~ (2017)
  42. Kany, S., "Cytokines in inflammatory disease", Int. J. Mol. Sci, 20, pp.6008~ (2019)
  43. Akdis, M., "Interleukins(from IL-1 to IL-38), interferons, transforming growth factor beta, and TNF-alpha : Receptors, functions, and roles in diseases", J. Allergy Clin. Immunol, 138, pp.984~1010 (2016)
  44. Slifka, M. K., "Clinical implications of dysregulated cytokine pro duction", J. Mol. Med. Berl, 78, pp.74~80 (2000)
  45. Labani-Motlagh, A., "The tumor microenviron ment : a milieu hindering and obstructing antitumor immune responses", Front. Immunol, 11, pp.940~ (2020)
  46. Briukhovetska, D., "Interleukins in cancer : from biology to therapy", Nat. Rev. Cancer, 21, pp.481~499 (2021)
  47. Haga, A., "Autocrine motility factor signaling induces tumor apoptotic resistance by regulations Apaf-1 and Caspase-9 apoptosome expression", Int J. Cancer, 107, pp.707~714 (2003)
  48. Kartikasari, A. E. R., "Tumor-induced inflammatory cytokines and the emerging diagnostic devices for cancer detection and prognosis", Front. Oncol, 11, pp.692142~ (2021)
  49. Bien, E., "Serum soluble interleukin 2 receptor alpha in human cancer of adults and children : a review", Biomarkers, 13, pp.1~26 (2008)
  50. Liao, W., "Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy", Immunity, 38, pp.13~25 (2013)
  51. Sheu, B. C., "A novel role of metalloproteinase in cancer-mediated immu nosuppression", Cancer Res, 61, pp.237~242 (2001)
  52. El Houda Agueznay, N., "Soluble interleukin-2 receptor and metalloproteinase-9 expression in head and neck cancer : prognostic value and analysis of their relationships", Clin. Exp. Immunol, 150, pp.114~123 (2007)
  53. Rubin, L. A., "The molecular basis for the generation of the human soluble interleukin 2 receptor", Cytokine, 2, pp.330~336 (1990)
  54. Rubinstein, M. P., "Converting IL-15 to a superagonist by binding to soluble IL-15Ralpha", Proc. Natl Acad. Sci. USA, 103, pp.9166~9171 (2006)
  55. Yang, Z. Z., "Soluble IL-2Ralpha facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma", Blood, 118, pp.2809~2820 (2011)
  56. Tartour, E., "Serum soluble interleukin-2 receptor concentrations as an independent prognostic marker in head and neck cancer", Lancet, 357, pp.1263~1264 (2001)
  57. Yoshida, N., "Clinical significance of sIL-2R levels in B-cell lymphomas", PLoS One, 8, pp.e78730~ (2013)
  58. Izzo, F., "Soluble interleukin-2 receptor levels in hepatocellular cancer : a more sensitive marker than alfa fetoprotein", Ann. Surg. Oncol, 6, pp.178~185 (1999)
  59. Ottaiano, A., "Soluble interleukin-2 receptor in stage I-III melanoma", Cytokine, 33, pp.150~155 (2006)
  60. Hunter, C. A., "IL-6 as a keystone cytokine in health and disease", Nat. Immunol, 16, pp.448~457 (2015)
  61. Skiniotis, G., "Signaling conformations of the tall cytokine receptor gp130 when in complex with IL-6 and IL-6 receptor", Nat. Struct. Mol. Biol, 12, pp.545~551 (2005)
  62. Johnson, D. E., "Targeting the IL-6", JAK, Nat. Rev. Clin. Oncol, pp.2018, 15[DOI]
  63. Chalaris, A., "The soluble Inter leukin 6 receptor : generation and role in inflammation and cancer", Eur. J. Cell Biol, 90, pp.484~494 (2011)
  64. Lesina, M., "Stat3", Socs3 activation by IL-6 transsignaling promotes pro gression of pancreatic intraepithelial neoplasia and development of pancreatic cancer, 2011, pp.19, 456~469
  65. Grivennikov, S., "IL-6 and Stat3 are required for survival of intestinal epi thelial cells and development of colitis-associated cancer", Cancer Cell, 15, pp.103~113 (2009)
  66. Matsumoto, S., "Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6", soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model, 2010, pp.184, 1543~1551
  67. Becker, C., "TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling", Immunity, 21, pp.491~501 (2004)
  68. Becker, C., "IL-6 signaling promotes tumor growth in colorectal cancer", Cell Cycle, 4, pp.217~220 (2005)
  69. Tsukamoto, H., "Soluble IL6R expressed by myeloid cells reduces tumor specific Th1 differentiation and drives tumor progression", Cancer Res, 77, pp.2279~2291 (2017)
  70. Jiang, M., "Interleukin-6 trans-signaling pathway promotes immunosup pressive myeloid-derived suppressor cells via suppression of suppressor of cytokine signaling 3 in breast cancer", Front. Immunol, 8, pp.1840~ (2017)
  71. Kalliolias, G. D., "TNF biology, pathogenic mechanisms and emerging therapeutic strategies", Nat. Rev. Rheumatol, 12, pp.49~62 (2016)
  72. Dri, P., "TNF-Induced shedding of TNF receptors in human polymorpho nuclear leukocytes : role of the 55-kDa TNF receptor and involvement of a membrane-bound and non-matrix metalloproteinase", J. Immunol, 165, pp.2165~2172 (2000)
  73. Niewczas, M. A., "Circulating TNF receptors 1 and 2 predict ESRD in type 2diabetes", J. Am. Soc. Nephrol, 23, pp.507~515 (2012)
  74. Carlsson, A. C., "Association of soluble tumor necrosis factor receptors 1 and 2 with nephropathy, cardiovascular events, and total mortality in type 2 dia betes", Cardiovasc. Diabetol, 15, pp.40~ (2016)
  75. Chen, X., "Co-expression of TNFR2 and CD25 identifies more of the func tional CD4+FOXP3+ regulatory T cells in human peripheral blood", Eur. J. Immunol, 40, pp.1099~1106 (2010)
  76. Chen, X., "Cutting edge : expression of TNFR2 defines a maximally sup pressive subset of mouse CD4+CD25+FoxP3+ T regulatory cells : applicability to tumor-infiltrating T regulatory cells", J. Immunol, 180, pp.6467~6471 (2008)
  77. Ye, L. L., "The significance of tumor necrosis factor receptor type II in CD8(+)regulatory T cells and CD8(+)effector T cells", Front. Immunol, 9, pp.583~ (2018)
  78. Williams, G. S., "Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy", Oncotarget, 7, pp.68278~68291 (2016)
  79. Sasi, S. P., "Breaking the ‘harmony’ of TNF-alpha signaling for cancer treatment", Oncogene, 31, pp.4117~4127 (2012)
  80. Kartikasari, A. E. R., "Elevation of circulating TNF receptor 2 in cancer : a systematic meta-analysis for its potential as a diagnostic cancer biomarker", Front. Immunol, 13, pp.918254~ (2022)
  81. Sharma, P., "The future of immune checkpoint therapy", Science, 348, pp.56~61 (2015)
  82. Korman, A. J., "The foundations of immune checkpoint blockade and the ipilimumab approval decennial", Nat. Rev. Drug Discov, 21, pp.509~528 (2022)
  83. Osipov, A., "Tumor mutational burden, toxicity, and response of immune checkpoint inhibitors targeting PD(L)1, CTLA-4, and combination : a meta regression analysis", Clin. Cancer Res, 26, pp.4842~4851 (2020)
  84. Hodi, F. S., "Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma : 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial", Lancet Oncol, 17, pp.1558~1568 (2016)
  85. Larkin, J., "Five-year survival with combined Nivolumab and Ipilimumab in advanced melanoma", N. Engl. J. Med, 381, pp.1535~1546 (2019)
  86. Frigola, X., "Identification of a soluble form of B7-H1 that retains immuno suppressive activity and is associated with aggressive renal cell carcinoma", Clin. Cancer Res, 17, pp.1915~1923 (2011)
  87. Frigola, X., "Soluble B7-H1 : differences in production between dendritic cells and T cells", Immunol. Lett, 142, pp.78~82 (2012)
  88. Chen, Y., "Development of a sandwich ELISA for evaluating soluble PD-L1(CD274)in human sera of different ages as well as supernatants of PD-L1+ cell lines", Cytokine, 56, pp.231~238 (2011)
  89. Ward, F. J., "The soluble isoform of CTLA-4 as a regulator of T-cell responses", Eur. J. Immunol, 43, pp.1274~1285 (2013)
  90. Laurent, S., "CTLA-4 is expressed by human monocyte-derived dendritic cells and regulates their functions", Hum. Immunol, 71, pp.934~941 (2010)
  91. Malinga, N. Z., "Systemic levels of the soluble co-inhibitory immune checkpoints, CTLA-4, LAG-3, PD-1", PD-L1 and TIM-3 are markedly increased in basal cell carcinoma, 2022, pp.19, 101384~
  92. Wang, Q., "Soluble immune checkpoint-related proteins in blood are associated with invasion and progression in non-small cell lung cancer", Front. Immunol, 13, pp.887916~ (2022)
  93. Leung, A. M., "Clinical benefit from Ipilimumab therapy in melanoma patients may be associated with serum CTLA4 levels", Front Oncol, 4, pp.110~ (2014)
  94. Dong, M. P., "Clinical significance of circulating soluble immune checkpoint proteins in sorafenib-treated patients with advanced hepatocellular carcinoma", Sci. Rep, 10, pp.3392~ (2020)
  95. Machiraju, D., "Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients", Oncoim munology, 10, pp.1926762~ (2021)
  96. Nakata, B., "Serum soluble interleukin-2 receptor level as a prognostic indicator in gastric cancer", Br. J. Cancer, 77, pp.1820~1824 (1998)
  97. Cabrera, R., "Serum levels of soluble CD25 as a marker for hepatocellular carcinoma", Oncol. Lett, 4, pp.840~846 (2012)
  98. Hashimoto, Y., "Prognostic importance of the soluble form of IL-2 recep toralpha(sIL-2Ralpha)and its relationship with surface expression of IL-2Ralpha(CD25)of lymphoma cells in diffuse large B-cell lymphoma treated with CHOP like regimen with or without rituximab : a retrospective analysis of 338 cases", J. Clin. Exp. Hematop, 53, pp.197~205 (2013)
  99. Rose-John, S., "Blocking only the bad side of IL-6 in inflammation and cancer", Cytokine, 148, pp.155690~ (2021)
  100. John, R. S., "Targeting IL-6 trans signalling : past", Nat. Rev. Immunol, 23, pp.666~681 (2023)
  101. Garbers, C., "Interleukin-6 : designing specific therapeutics for a complex cytokine", Nat. Rev. Drug Discov, 17, pp.395~412 (2018)
  102. Group, R. C., "Tocilizumab in patients admitted to hospital with COVID-19(RECOVERY) : a randomised, controlled, open-label, platform trial", Lancet, 397, pp.1637~1645 (2021)
  103. Boyce, E. G., "Sarilumab : review of a second IL-6 receptor antagonist indicated for the treatment of rheumatoid arthritis", Ann. Pharmacother, 52, pp.780~791 (2018)
  104. Jostock, T., "Soluble gp130 is the natural inhibitor of soluble interleukin-6receptor transsignaling responses", Eur. J. Biochem, 268, pp.160~167 (2001)
  105. Bergmann, J., "IL-6 trans-signaling is essential for the development of hepatocellular carcinoma in mice", Hepatology, 65, pp.89~103 (2017)
  106. Rosenberg, N., "Combined hepatocellular-cholangiocarcinoma derives from liver progenitor cells and depends on senescence and IL-6 trans-signaling", J. Hepatol, 77, pp.1631~1641 (2022)
  107. Govindaraj, C., "Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+ Tregs within the tumor microenvironment", Clin. Immunol, 149, pp.97~110 (2013)
  108. Govindaraj, C., "Reducing TNF receptor 2+ regulatory T cells via the combined action of azacitidine and the HDAC inhibitor, panobinostat for clinical benefit in acute myeloid leukemia patients", Clin. Cancer Res, 20, pp.724~735 (2014)
  109. Yan, F., "Expression of TNFR2 by regulatory T cells in peripheral blood is correlated with clinical pathology of lung cancer patients", Cancer Immunol. Immunother, 64, pp.1475~1485 (2015)
  110. Torrey, H., "Targeting TNFR2 with antagonistic antibodies inhibits pro liferation of ovarian cancer cells and tumor-associated Tregs", Sci. Signal, 10, pp.eaaf8608~ (2017)
  111. Saftig, P., "The “A disintegrin and metalloproteases” ADAM10 and ADAM17: novel drug targets with therapeutic potential?", Eur. J. Cell Biol, 90, pp.527~535 (2011)
  112. Mullooly, M., "The ADAMs family of proteases as targets for the treatment of cancer", Cancer Biol. Ther, 17, pp.870~880 (2016)
  113. Witters, L., "Synergistic inhibition with a dual epidermal growth factor receptor", HER-2, Cancer Res, pp.2008, 68[DOI]
  114. Saha, N., "ADAM proteases : emerging role and targeting of the non-catalytic domains", Cancer Lett, 467, pp.50~57 (2019)
  115. Andrews, L. P., "Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups", Nat. Immunol, 20, pp.1425~1434 (2019)
  116. Balic, J. J., "Interleukin-11-driven gastric tumourigenesis is independent of trans-signalling", Cytokine, 92, pp.118~123 (2017)
  117. Berg, A. F., "Exclusive inhibition of IL-6 trans-signaling by soluble gp130(FlyR)Fc", Cytokine X, 3, pp.100058~ (2021)
  118. Heise, D., "Selective inhibition of IL-6 trans-signaling by a miniaturized, optimized chimeric soluble gp130 inhibits T(H)17 cell expansion", Sci. Signal, 14, pp.eabc3480~ (2021)
  119. Rios-Doria, J., "A monoclonal antibody to ADAM17 inhibits tumor growth by inhibiting EGFR and non-EGFR-mediated pathways", Mol. Cancer Ther, 14, pp.1637~1649 (2015)
  120. Allen-Mersh, T. G., "Relation between depression and circulating immune products in patients with advanced colorectal cancer", J. R. Soc. Med, 91, pp.408~413 (1998)
  121. Sakata, H., "Serum soluble interleukin-2 receptor (IL 2R) and immunohistochemical staining of IL-2R", Tac antigen in colorectal cancer, 2002, pp.7, 312~317
  122. Gonda, K., "Serum soluble interleukin-2 receptor is increased in mal nourished and immunosuppressed patients with gastric and colorectal cancer : possible influence of myeloid-derived suppressor cells", World J. Oncol, 3, pp.158~164 (2012)
  123. Murakami, S., "Serum-soluble interleukin-2 receptor concentrations in patients with gastric cancer", Cancer, 74, pp.2745~2748 (1994)
  124. Murakami, S., "Serum soluble interleukin-2 receptor and immunohisto chemical staining of IL-2R", Tac antigen in gastric cancer, 1996, pp.3, 69~73
  125. Oka, M., "Relationship between serum levels of soluble interleukin-2receptor and various disease parameters in patients with squamous cell carci noma of the esophagus", Hepatogastro. Enterol, 46, pp.2254~2259 (1999)
  126. Wang, L. S., "Clinical significance of serum soluble interleukin 2 receptor alpha in esophageal squamous cell carcinoma", Clin. Cancer Res, 6, pp.1445~1451 (2000)
  127. Gross, M., "The diagnostic and prognostic value of sIL-2R as an immune biomarker in head and neck cancers", Anticancer Res, 36, pp.4347~4352 (2016)
  128. Tartour, E., "Soluble interleukin-2 receptor serum level as a predictor of locoregional control and survival for patients with head and neck carci noma : results of a multivariate prospective study", Cancer, 79, pp.1401~1408 (1997)
  129. Murakami, J., "Serum soluble interleukin-2 receptor levels for screening for malignant lymphomas and differential diagnosis from other conditions", Mol. Clin. Oncol, 11, pp.474~482 (2019)
  130. Stasi, R., "The prognostic value of soluble interleukin-6 receptor in patients with multiple myeloma", Cancer, 82, pp.1860~1866 (1998)
  131. Alexandrakis, M. G., "Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma", Ann. Hematol, 82, pp.19~23 (2003)
  132. Van Zaanen, H. C., "Blocking interleukin-6 activity with chimeric anti-IL6monoclonal antibodies in multiple myeloma : effects on soluble IL6 receptor and soluble gp130", Leuk. Lymphoma, 31, pp.551~558 (1998)
  133. Jablonska, E., "Changes in soluble IL-6 receptor and IL-6 production by polymorphonuclear cells and whole blood cells of breast cancer patients", Arch. Immunol. Ther. Exp. Warsz, 46, pp.25~29 (1998)
  134. Jablonska, E., "Changes in sIL-6R and sTNF-Rs release by PMNs and the serum levels in breast cancer patients at different stages of treatment", Cytokine, 10, pp.540~543 (1998)
  135. Jablonska, E., "TNF-alpha, IL-6 and their soluble receptor serum levels and secretion by neu trophils in cancer patients", Arch. Immunol. Ther. Exp. Warsz, 49, pp.63~69 (2001)
  136. Robak, T., "Serum levels of IL-6 type cytokines and soluble IL-6 receptors in active B-cell chronic lymphocytic leukemia and in cladribine induced remission", Mediat. Inflamm, 8, pp.277~286 (1999)
  137. Babic, A., "Soluble tumour necrosis factor receptor type II and survival in colorectal cancer", Br. J. Cancer, 114, pp.995~1002 (2016)
  138. Chan A. T., "Inflammatory markers are associated with risk of colorectal cancer and chemopreventive response to anti inflammatory drugs", Gastroenterology, 140, pp.799~808 (2011)
  139. Hamaguchi, T., "Exploration of potential prognostic biomarkers in afli bercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer", Cancer Sci, 110, pp.3565~3572 (2019)
  140. Zeng, F., "Inflammatory markers of CRP, IL6, TNFalpha, and soluble TNFR2and the risk of ovarian cancer : a meta-analysis of prospective studies", Cancer Epidemiol. Biomark. Prev, 25, pp.1231~1239 (2016)
  141. Nomelini, R. S., "TNF-R2 in tumor microenvironment as prognostic factor in epithelial ovarian cancer", Clin. Exp. Med, 18, pp.547~554 (2018)
  142. Dobrzycka, B., "Circulating levels of TNF-alpha and its soluble receptors in the plasma of patients with epithelial ovarian cancer", Eur. Cytokine Netw, 20, pp.131~134 (2009)
  143. Nakamura, N., "Serum level of soluble tumor necrosis factor receptor 2 is associated with the outcome of patients with diffuse large B-cell lymphoma treated with the R-CHOP regimen", Eur. J. Haematol, 91, pp.322~331 (2013)
  144. Goto, N., "Serum-soluble tumor necrosis factor receptor 2(sTNF-R2)level determines clinical outcome in patients with aggressive non-Hodgkin’s lym phoma", Eur. J. Haematol, 77, pp.217~225 (2006)
  145. Casasnovas, R. O., "Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin’s lymphoma : a study from the Groupe d’Etude des Lymphomes de l’Adulte", J. Clin. Oncol, 25, pp.1732~1740 (2007)
  146. Heemann, C., "Circulating levels of TNF receptor II are prognostic for patients with peripheral T-cell non-Hodgkin lymphoma", Clin. Cancer Res, 18, pp.3637~3647 (2012)
  147. Shiels, M. S., "Circulating inflammation markers, risk of lung cancer, and utility for risk stratification", J. Natl Cancer Inst, 107, pp.djv199~ (2015)
  148. Gregorc, V., "Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer", Cancer, 110, pp.845~853 (2007)
  149. Chen, J., "Increased serum soluble IL-15Ralpha levels in T-cell large granular lymphocyte leukemia", Blood, 119, pp.137~143 (2012)
  150. Peng, Y., "A comprehensive profiling of soluble immune checkpoints from the sera of patients with non-small cell lung cancer", J. Clin. Lab Anal, 36, pp.e24224~ (2022)
  151. Zhang, G., "Diagnosis value of serum B7-H3 expression in non-small cell lung cancer", Lung Cancer, 66, pp.245~249 (2009)
  152. Mu, C. Y., "Soluble CD40 in plasma and malignant pleural effusion with non-small cell lung cancer : A potential marker of prognosis", Chronic Dis. Transl. Med, 1, pp.36~41 (2015)
  153. Zhang, J., "Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics", Thorac. Cancer, 6, pp.534~538 (2015)
  154. Cheng, H. Y., "Circulating programmed death-1 as a marker for sustained high hepatitis B viral load and risk of hepatocellular carcinoma", PLoS One, 9, pp.e95870~ (2014)
  155. Finkelmeier, F., "High levels of the soluble programmed death-ligand(sPD L1)identify hepatocellular carcinoma patients with a poor prognosis", Eur. J. Cancer, 59, pp.152~159 (2016)
  156. Simone, R., "A soluble form of CTLA-4 is present in paediatric patients with acute lymphoblastic leukaemia and correlates with CD1d+ expression", PLoS One, 7, pp.e44654~ (2012)
  157. Hock, B. D., "Identification of a circulating soluble form of CD80 : levels in patients with hematological malignancies", Leuk. Lymphoma, 45, pp.2111~2118 (2004)
  158. Rossille, D., "High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma : results from a French multicenter clinical trial", Leukemia, 28, pp.2367~2375 (2014)
  159. Guo, X., "High serum level of soluble programmed death Ligand 1 is associated with a poor prognosis in hodgkin lymphoma", Transl. Oncol, 11, pp.779~785 (2018)
  160. Bi, X. W., "PD-L1 is upregulated by EBV-driven LMP1 through NF-kappaB pathway and correlates with poor prognosis in natural killer", T-cell lymphoma, 2016, pp.9, 109~

관련 논문AI추천

The Diverse Function of IL-6 in Biological Processes and the Advancement of CancerSong Xiaofeng, Ying Zhou, Yongli Li, Yuan Miaomiao대한면역학회 · Immune Network2025 · 제25권 제3호Shedding; towards a new paradigm of syndecan function in cancer오억수, 이하원, Jung Ran Choi, Sojoong Choi생화학분자생물학회 · BMB Reports2010 · 제43권 제5호Proteolytic cleavages of MET: the divide-and-conquer strategy of a receptor tyrosine kinaseDavid Tulasne, Leslie Duplaquet, Marie Fernandes생화학분자생물학회 · BMB Reports2019 · 제52권 제4호Tumor Therapy Applying Membrane-bound Form of Cytokines김영상대한면역학회 · Immune Network2009 · 제9권 제5호Cytokine Signaling in Tumor Progression이명미, 이인무대한면역학회 · Immune Network2017 · 제17권 제4호Targeted inhibition of tumor-derived exosomes as a novel therapeutic option for cancerChen Gang, Chen Zhuo-Kun, Duan Xu, Li Ye, Wang Kui-Ming, Xiao Bo-Lin, Zhang He-Jing생화학분자생물학회 · Experimental and Molecular Medicine2022 · 제54권

이 간행물의 다른 논문 (218건)

Big data and deep learning for RNA biologyJeon Hyeonseong, Baek Daehyun, Hwang Hyeonseo, Yeo Nagyeongpp. 1-29RGS19 activates the MYH9/β-catenin/c-Myc positive feedback loop in hepatocellular carcinomaXu Yanan, Ke Shanjia, Lu Shounan, Bai Miaoyu, Yu Hongjun, Yin Bing, Wang Chaoqun, Feng Zhigang, Li Zihao, Huang Jingjing, Li Xinglong, Qian Baolin, Hua Yongliang, Fu Yao, Sun Bei, Wu Yaohua, Ma Yongpp. 1-14Molecular mechanisms of circular RNA translationKim Yoon Ki, Hwang Hyun Jungpp. 1-9The m6A writer RBM15 drives the growth of triple-negative breast cancer cells through the stimulation of serine and glycine metabolismKim Ho, Yun Hye Jin, 이종호, Lee Su Bin, Kim Seok-Ho, Park Yun-Yong, Park Su Hwan, Ju Jin-Sung, Woo Hyunmin, Győrffy Balázs, Kim Eun-jeong, Han Hee Dong, Eyun Seong-ilpp. 1-15Neuron type-specific optogenetic stimulation for differential stroke recovery in chronic capsular infarctKim Ra Gyung, Cho Jongwook, Park Ji-Young, Kim Young Ro, Lee Min-Cheol, Kim Hyoung-Ihlpp. 1-11
원문 보기